Frank McCormick, PhD, FRS, DSc (Hon), discussed how RASolute-302 data showing daraxonrasib nearly doubled survival reshaped pancreatic cancer drug development.
Frank McCormick, PhD, FRS, DSc (Hon)
Advertisement
Articles by Frank McCormick, PhD, FRS, DSc (Hon)
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma
2
CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications
3
How KRAS-Targeted Therapy May Advance Toward Cancer Prevention
4
Subcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC
5